An improved method for isolation and purification of soluble tumor-associated proteins from the serum of cancer patients

Experimental Oncology

Volumn 21, Issue 1, 1999, Pages 55-58

  Sandler, B ^a   Smirnoff, P ^a   Ben Hur, H ^b   Zusman, R ^a   Zusman, I ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b KAPLAN MEDICAL CENTER   (Israel)

Author keywords

Affinity chromatography; Colon cancer; Gel fiberglass; IgG; Tumor associated antigens

Indexed keywords

EID: 0345734699     PISSN: 02043564     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Zusman I. Gel fiberglass membranes for affinity chromatography columns and their application to cancer detection. J Chromat B Biomed Sci Appl 1998; 715: 297-306.
2. Zusman R, Zusman I. Gel fiberglass as a new support for affinity chromatography. Biotechnol Appl Biochem 1995; 21: 161-72.
3. Zusman I, Zusman R, Korol D, et al. Isolation of p53 protein from the serum of colon cancer and non-cancer patients. Oncol Rep 1995; 2: 679-83.
4. Zusman I, Zusman R, Sandler B, et al. HPLC determination of serum levels of soluble p53 protein as a new method for colon cancer detection, and its clinical implication. Int J Oncol 1996; 8: 1249-56.
5. Ben-Hur H, Berman V, Sandler B, et al. Serological and immunohistochemical determinations of p53 protein in diagnosis of endometrial cancer: a comparative study. Eur J Gynaecol Oncol 1997; 18: 400-6.
6. Peterson GL. Determination of total protein. Methods Enzymol 1983; 91: 95-119.
7. Harlow E, Lane D. Antibodies. A Laboratory Manual. New York: Cold Spring Harbor Lab Publ, 1988.
8. Kang, K, Ryu D, Drohan WN, et al. Effect of matrices on affinity purification of protein C. Biotechnol Bioengin 1992; 39: 1086-96.
9. Brinker CJ, Scherer GW. Sol-gel science. New York: Acad Press, 1990.
10. Gusak TW, Tyn MT, Kinsella JE. Immobilization of the serine protease from Thermomonospora fusce YX on porous glass. Biotechnol Bioengin 1990; 36: 411-6.
11. Riitinen L, Narvanen O, Virtanen I, et al. Monoclonal antibodies against endometrial protein PP14 and their use for purification and radioimmunoassay of PP14. J Immunol Methods 1991; 136: 85-90.
12. Magdelenat H. Tumour markers in oncology: past, present and future. J Immunol Methods 1992; 150: 133-43.
13. Yi P, Sun X, Doerge DR, et al. An improved p32 postlabelling high performance liquid chromatography method for the analysis of the malondialdehye-derived 1, N2-Propanodeoxyguanosine DNA adduct in animal and human tissues. Chem Res Toxicol 1998; 11: 1032-41.
14. Maxwell SA. Two-dimensional gel analysis of p53-mediated changes in protein expression. Anticancer Res 1994; 14: 2549-56.
15. Sturzbechter HW, Deppert W. Structural and functional analysis of tumor suppressor p53. Methods Mol Genetics 1994; 5: 319-41.
16. Sugano K, Fukayama N, Ohkura H, et al. Single-strand conformation polymorphism analysis by perpendicular temperature-gradient gel electrophoresis. Electrophoresis 1995; 16: 8-10.
17. Angelopoulou K, Diamandis EP, Sutherland DJA, et al. Prevalence of serum antibodies against the p53 tumor suppressor gene protein in various cancers. Int J Cancer 1994; 58: 480-7.
18. Levesque MA, Dcosta M, Diamandis EP. p53 protein is absent from the serum of patients with lung cancer. Br J Cancer 1996; 74: 1434-40.
19. Park JS, Kim CJ, Um SJ, et al. Immune response to p53 and HPV-16 E6 proteins in patients with cervical cancer. Int J Gynecol Oncol 1998; 8: 328-35.
20. Ralhan R, Nath N, Agarwal S, et al. Circulating p53 antibodies as early markers of oral cancer: Correlation with p53 alterations. Clin Cancer Res 1998; 4: 2147-52.
21. Lizasa T, Fujisawa T, Saitoh Y, et al. Serum anti-p53 autoantibodies in primary resected non-small-cell lung carcinoma. Cancer Immunol Immunother 1998; 46: 345-9.
22. Sandler B, Smirnoff P, Shani A, et al. The role of the soluble p53 antigen and its autoantibodies as markers for diagnosis of colon cancer: A comparative study. Int J Mol Med 1998; 1: 453-7.